Elevance Health Beats Q1 Adjusted EPS by $1.78, Boosts Full-Year Guidance
ELV sits 24% above its 52-week low of $273.71.
Summary
Elevance Health reported robust first-quarter results, with adjusted EPS of $12.58, significantly outperforming the IBES estimate of $10.80. This strong beat signals better-than-anticipated operational performance. The company also raised its full-year adjusted EPS outlook to $26.75, exceeding the consensus estimate of $25.70, indicating confidence in continued momentum. This positive earnings surprise and upward revision to guidance are highly material for traders, likely prompting positive stock movement and analyst upgrades.
At the time of this announcement, ELV was trading at $340.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $72.1B. The 52-week trading range was $273.71 to $432.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.